{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104028","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.101562+00:00","generated_at":"2026-05-17T19:49:15.504521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress","bullets":["Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).","Cash, cash equivalents, and investments $142.4M as of June 30, 2025; funding into Q2 2027.","First patient treated in global Phase 2a basket trial of AlloNK + rituximab in refractory RA, Sjögren's, myositis, and scleroderma.","Over a dozen patients treated across autoimmune trials; initial safety/translational data by year-end 2025.","Lead indication for AlloNK to be disclosed by year-end 2025; initial clinical response data in 1H2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104028","json":"https://secwatch.observer/filing/0000950170-25-104028.json","markdown":"https://secwatch.observer/filing/0000950170-25-104028.md","text":"https://secwatch.observer/filing/0000950170-25-104028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/0000950170-25-104028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/artv-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:49:15.504521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}